Company Overview

Vaxil Bio Ltd. is a clinical-stage biotechnology company focused on the development of therapeutic vaccines for cancer and infectious diseases. The company operates within the biopharmaceutical and immuno-oncology industries, with its core scientific approach centered on T-cell–based immunotherapy. Vaxil Bio’s primary value proposition is the development of off-the-shelf peptide vaccines designed to stimulate targeted immune responses against disease-specific antigens.

The company’s principal product candidate is ImMucin, a therapeutic cancer vaccine targeting the MUC1 antigen, which is overexpressed in multiple solid and hematological malignancies. Vaxil Bio’s strategy emphasizes broad applicability across cancer types, combination use with existing therapies, and a relatively low-cost manufacturing profile compared with personalized cell therapies. The company was founded in Israel and became publicly listed on the TSX Venture Exchange under the ticker VXL.V, evolving from early-stage academic research into a publicly traded clinical development company.

Business Operations

Vaxil Bio’s operations are primarily focused on research and development, with no commercial-stage products and no recurring product revenue reported in public filings. Its activities include preclinical research, clinical trial design and execution, regulatory engagement, and intellectual property management related to peptide-based vaccines. The company does not maintain large-scale manufacturing facilities and relies on third-party contractors for clinical production and trial-related services.

Operationally, the company’s work has centered on advancing ImMucin through early-stage clinical trials in cancer indications, including multiple myeloma, as well as exploratory research into infectious disease applications. Vaxil Bio operates mainly through its Israeli subsidiary, Vaxil Bio Therapeutics Ltd., which houses its R&D personnel and intellectual property. Public disclosures indicate limited headcount and a lean operational structure consistent with early-stage biotechnology firms.

Strategic Position & Investments

Vaxil Bio’s strategic direction is focused on advancing ImMucin through clinical development and seeking strategic partnerships or licensing opportunities with larger pharmaceutical or biotechnology companies. Growth initiatives have historically emphasized demonstrating clinical proof-of-concept, expanding potential indications, and evaluating combination therapy opportunities with established cancer treatments such as checkpoint inhibitors.

The company has not disclosed any material acquisitions of other companies, nor does it report ownership of a diversified portfolio of subsidiaries. Investment activity has primarily involved internal R&D spending and capital raises through equity financing to fund ongoing operations. Vaxil Bio has also publicly indicated interest in applying its vaccine platform to infectious diseases, though available public data indicates these efforts remain at an exploratory or preclinical stage, and outcomes are data inconclusive based on available public sources.

Geographic Footprint

Vaxil Bio is headquartered in Israel, which serves as the center of its research and corporate operations. The company’s clinical and regulatory activities extend internationally through collaborations with research institutions, clinical trial sites, and contract research organizations, primarily in North America and Europe, depending on trial design and regulatory requirements.

As a publicly traded company on the Canadian capital markets, Vaxil Bio maintains investor relations and regulatory reporting obligations in Canada, while its operational influence remains concentrated in the Middle East and Western markets associated with clinical research and biotechnology investment. There is no public evidence of commercial operations or manufacturing facilities outside these regions.

Leadership & Governance

Vaxil Bio is governed by a board of directors and a small executive team with backgrounds in biotechnology, immunology, and corporate management. The leadership philosophy, as reflected in public disclosures, emphasizes scientific validation, capital efficiency, and strategic collaboration to advance assets through value-inflection points rather than building large in-house infrastructure.

Key executives and leaders disclosed in public filings include:

• Gadi Levin – Chief Executive Officer
• Yoram Shacham – Chairman of the Board
• Dr. Hadas Reuveni – Scientific Advisor
• Yaron Cohen – Chief Financial Officer

The company’s governance framework follows standard public company practices for early-stage life sciences firms, with oversight focused on clinical development progress, regulatory compliance, and capital management.